Acta Diabetologica

, Volume 49, Issue 4, pp 243–254

Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes

Review Article


Cardiovascular disease is the predominant cause of morbidity in people with type 2 diabetes. Hypertension frequently coexists with diabetes and substantially increases the risk of developing end-organ damage. Controlling hypertension in patients with diabetes is therefore critical to reducing microvascular and macrovascular complications. Agents that block the renin-angiotensin system are increasingly used in patients with diabetes based on their cardiovascular and renoprotective effects, in addition to their direct effects on reducing blood pressure. Telmisartan, an angiotensin II receptor blocker (ARB), has a number of distinguishing pharmacological properties such as having the longest half-life and highest lipophilicity in its class. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET®) trial showed that telmisartan reduces cardiovascular morbidity (including myocardial infarction and stroke) in subjects with a broad spectrum of cardiovascular risk factors, including type 2 diabetes. Telmisartan is the only ARB indicated for the reduction of cardiovascular morbidity in patients with diabetes and end-organ damage, as well as in patients without diabetes but with a history of coronary artery disease, peripheral artery disease, or previous stroke. Trials of telmisartan in patients with diabetes and varying degrees of nephropathy also suggest that this drug can slow the progression of renal disease, an effect that appears to be at least partly independent of reduction in blood pressure. Telmisartan is therefore an important therapeutic option for optimizing cardiovascular and renal protection in the type 2 diabetic population.


Cardiovascular disease Type 2 diabetes Risk reduction Renal protection Telmisartan 


  1. 1.
    Mathers CD, Loncar D (2006) Projections of global mortality, burden of disease from 2002 to 2030. PLoS Med 3:e442PubMedCrossRefGoogle Scholar
  2. 2.
    Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234PubMedCrossRefGoogle Scholar
  3. 3.
    National Diabetes Information Clearinghouse [NDIC] (2007)Google Scholar
  4. 4.
    Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G et al (2010) Heart disease and stroke statistics 2010 update: a report from the American Heart Association. Circulation 121:e46–e215. Available at: Accessed 11 July 2010Google Scholar
  5. 5.
    WHO Fact sheet N°311 (2006)Google Scholar
  6. 6.
    International Diabetes Federation (2010) Diabetes atlas, 4th edn. Available at: Accessed April 2010
  7. 7.
    American Diabetes Association (ADA) (2003) Treatment of hypertension in adults with diabetes. Diabetes Care 2(Suppl 1):S80–S82Google Scholar
  8. 8.
    Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors and 12-years cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16:434–444PubMedCrossRefGoogle Scholar
  9. 9.
    Cea-Calvo L, Conthe P, Gómez-Fernández P, de Alvaro F, Fernández-Pérez C, RICARHD Investigators (2006) Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study. Cardiovasc Diabetol 5:23PubMedCrossRefGoogle Scholar
  10. 10.
    Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, EUROASPIRE Study Group (2009) EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 16:121–137PubMedCrossRefGoogle Scholar
  11. 11.
    Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937–952PubMedCrossRefGoogle Scholar
  12. 12.
    American Association of Clinical Endocrinologists (AACE) (2010) State of diabetes complications in America report 2007. Available at: Accessed 11 July 2010
  13. 13.
    Tarquini R, Lazzeri C, Pala L, Rotella CM, Gensini GF (2010) The diabetic cardiomyopathy. Acta Diabetol [Epub ahead of print]Google Scholar
  14. 14.
    American Diabetes Association (ADA) (2010) Standards of medical care in diabetes 2010. Diabetes Care 33(Suppl 1):S11–S61. Available at: Accessed 11 July 2010Google Scholar
  15. 15.
    Radermecker RP, Philips JC, Jandrain B, Paquot N, Scheen AJ (2008) Blood glucose control and cardiovascular disease in patients with type 2 diabetes. Results of ACCORD, ADVANCE and VA-Diabetes trials. Rev Med Liege 63:511–518PubMedGoogle Scholar
  16. 16.
    Staessen JA, Li Y, Thijs L, Wang JG (2005) Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res 28:385–407PubMedCrossRefGoogle Scholar
  17. 17.
    Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, EUROASPIRE Study Group (2009) Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373:929–940PubMedCrossRefGoogle Scholar
  18. 18.
    Wong ND, Lopez VA, L’Italien G, Chen R, Kline SE, Franklin SS (2007) Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003–2004. Arch Intern Med 167:2431–2436PubMedCrossRefGoogle Scholar
  19. 19.
    Centers for Disease Control, Prevention (2003) National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2002. Centers for Disease Control and Prevention, Atlanta, GAGoogle Scholar
  20. 20.
    Adler AI, Stratton IM, Neil HAW, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR, on behalf of the United Kingdom Prospective Diabetes Study Group (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes: UKPDS 36. BMJ 321:412–419PubMedCrossRefGoogle Scholar
  21. 21.
    BPLTTC Blood Pressure Lowering Treatment Trialist’s Collaboration (2005) Effects of different blood pressure lowering treatment regimens on major cardiovascular events in patients with and without diabetes mellitus. Arch Intern Med 165:1410–1419CrossRefGoogle Scholar
  22. 22.
    Chobhanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee (2003) The seventh report of the Joint national committee on prevention, detection, evaluation, and treatment of high blood pressure; the JNC 7 report. JAMA 89:2560–2572Google Scholar
  23. 23.
    Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B, Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology (2007) Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28:1462–1536PubMedGoogle Scholar
  24. 24.
    Dzau V, Braunwald E (1991) Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 121:1244–1263PubMedCrossRefGoogle Scholar
  25. 25.
    Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W (2006) The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 114:2850–2870PubMedCrossRefGoogle Scholar
  26. 26.
    Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM (2007) Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 30:1351–1356PubMedCrossRefGoogle Scholar
  27. 27.
    Morawietz H (2006) Endothelial protection, AT1 blockade and cholesterol-dependent oxidative stress: the EPAS trial. Circulation 114:1S–296SCrossRefGoogle Scholar
  28. 28.
    Unger T (2002) The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89(Suppl):3A–10APubMedCrossRefGoogle Scholar
  29. 29.
    Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. The HOPE study investigators. N Engl J Med 342:145–153PubMedCrossRefGoogle Scholar
  30. 30.
    Dicpinigaitis PV (2006) Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 129(Suppl 1):1695–1735Google Scholar
  31. 31.
    Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE (2008) Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 51:1624–1630PubMedCrossRefGoogle Scholar
  32. 32.
    Weber MA, Messerli FH (2008) Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension 51:1465–1467PubMedCrossRefGoogle Scholar
  33. 33.
    Crowley SD, Gurley SB, Coffman TM (2007) AT1 receptors and control of blood pressure: the kidney and more. Trends Cardiovasc Med 17(1):30–34PubMedCrossRefGoogle Scholar
  34. 34.
    Emre M, Kavak S, Unlugenc H (2010) The effects of telmisartan on mechanical responses of left ventricular papillary muscle in rats with streptozotocin-induced diabetes mellitus. Acta Diabetol 47(Suppl 1):153–159PubMedCrossRefGoogle Scholar
  35. 35.
    Steckelings UM, Kaschina E, Unger T et al (2005) The AT2 receptor—matter of love and hate. Peptides 26:1401–1409PubMedCrossRefGoogle Scholar
  36. 36.
    Kurtz TW, Pravenec M (2008) Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system. Am J Hypertens 21:852–859PubMedCrossRefGoogle Scholar
  37. 37.
    Burnier M (2009) Telmisartan: a different angiotensin II receptor blocker protecting a different population? J Int Med Res 37:1662–1679PubMedGoogle Scholar
  38. 38.
    Chambers S (2008) Telmisartan: an effective antihypertensive for 24-hour blood pressure control. Drugs Context 4:1–14Google Scholar
  39. 39.
    Wienen W, Entzeroth M, van Meel JCA, Stangier J, Busch U, Ebner T, Schmid J, Lehmann H, Matzek K, Kempthorne-Rawson J, Gladigau V, Hauel NH (2000) A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev 18:127–156CrossRefGoogle Scholar
  40. 40.
    Maillard MP, Perregaux C, Centeno C, Stangier J, Wienen W, Brunner HR, Burnier M (2002) In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther 302:1089–1095PubMedCrossRefGoogle Scholar
  41. 41.
    Kakuta H, Sudoh K, Sasamata M, Yamagishi S (2005) Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 25:41–46PubMedGoogle Scholar
  42. 42.
    Stangier J, Su CA, Roth W (2000) Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 28:149–167PubMedGoogle Scholar
  43. 43.
    Stangier J, Schmid J, Türck D, Switek H, Verhagen A, Peeters PA, van Marle SP, Tamminga WJ, Sollie FA, Jonkman JH (2000) Absorption, metabolism, and excretion of intravenously and orally administered [14C] telmisartan in healthy volunteers. J Clin Pharmacol 40:1312–1322PubMedGoogle Scholar
  44. 44.
    Israili ZH (2000) Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 14(Suppl 1):S73–S86PubMedCrossRefGoogle Scholar
  45. 45.
    Ebner T, Heinzel G, Prox A, Beschke K, Wachsmuth H (1999) Disposition and chemical stability of telmisartan 1-O-acylglucuronide. Drug Metab Dispos 27:1143–1149PubMedGoogle Scholar
  46. 46.
    European Medicines Agency (2009) MICARDIS® (telmisartan): summary of product characteristics 25 May 2009. Available at: Accessed 11 July 2010
  47. 47.
    Battershill AJ, Scott LJ (2006) Telmisartan: a review of its use in the management of hypertension. Drugs 66:51–83PubMedCrossRefGoogle Scholar
  48. 48.
    Schumacher H, Mancia G (2008) The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press 17(Suppl 1):32–40CrossRefGoogle Scholar
  49. 49.
    Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A, European Society of Hypertension (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension task force document. J Hypertens 27:2121–2158PubMedCrossRefGoogle Scholar
  50. 50.
    National Institute for Health and Clinical Excellence (NICE) (2006) Hypertension: NICE guideline. Available at:
  51. 51.
    Sharma AM, Davidson J, Koval S, Lacourcière Y (2007) Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol 6:28PubMedCrossRefGoogle Scholar
  52. 52.
    Littlejohn TW III, Majul CR, Olvera R, Seeber M, Kobe M, Guthrie R, Oigman W, Study Investigators (2009) Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 11:207–213CrossRefGoogle Scholar
  53. 53.
    Littlejohn T III, Raskin P, Neutel, Majul CR, Oigman W, Olvera R, Seeber M, Kobe M, Schumacher H (2009) Telmisartan in combination with amlodipine provides a highly effective and well-tolerated treatment option for hypertensive patients with diabetes: sub-analysis from a factorial design study. Poster presentation at ESHGoogle Scholar
  54. 54.
    Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C, for the ONTARGET® Investigators (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559Google Scholar
  55. 55.
    Teo K, Yusuf S, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H, ONTARGET®/TRANSCEND® Investigators (2004) Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET®/TRANSCEND®) trials. Am Heart J 148:52–61Google Scholar
  56. 56.
    Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al; LIFE Study Group (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995–1003Google Scholar
  57. 57.
    Yuan L, Li X, Li J, Li HL, Cheng SS (2010) Effects of renin-angiotensin system blockade on the islet morphology and function in rats with long-term high-fat diet. Acta Diabetol [Epub ahead of print]Google Scholar
  58. 58.
    Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L et al (1987) Insulin resistance in essential hypertension. N Engl J Med 317:350–357PubMedCrossRefGoogle Scholar
  59. 59.
    Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP (1997) Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100:2158–2169PubMedCrossRefGoogle Scholar
  60. 60.
    Andreozzi F, Laratta E, Sciacqua A, Perticone F, Sesti G (2004) Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Circ Res 94:1211–1218PubMedCrossRefGoogle Scholar
  61. 61.
    Kurtz TW, Klein U (2009) Next generation multifunctional angiotensin receptor blockers. Hypertens Res 32:826–834PubMedCrossRefGoogle Scholar
  62. 62.
    Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, for the TRANSCEND® Investigators (2008) Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 27(372):1174–1183Google Scholar
  63. 63.
    Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW, PRoFESS® Study Group (2008) Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359:1225–1237Google Scholar
  64. 64.
    Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355:1551–1562PubMedCrossRefGoogle Scholar
  65. 65.
    Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S (2006) Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368:581–588PubMedCrossRefGoogle Scholar
  66. 66.
    Kimmelstiel P, Wilson C (1987) Intercapillary lesions in the glomeruli of the kidney. Am J Pathol 12:83–92Google Scholar
  67. 67.
    Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J, National Kidney Foundation Hypertension Diabetes Executive Committees Working Group (2000) Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 36:646–661PubMedCrossRefGoogle Scholar
  68. 68.
    Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S, INNOVATION® Study Group (2007) Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 30:1577–1578Google Scholar
  69. 69.
    Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan, Enalapril Study Group (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952–1961PubMedCrossRefGoogle Scholar
  70. 70.
    Barnett AH (2005) Preventing renal complications in diabetic patients: the diabetics exposed to telmisartan and enalaprIL (DETAIL®) study. Acta Diabetol 42(Suppl 1):S42–S49PubMedCrossRefGoogle Scholar
  71. 71.
    Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM (2007) Renin-angiotensin system and cardiovascular risk. Lancet 369:1208–1219PubMedCrossRefGoogle Scholar
  72. 72.
    Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, for the ONTARGET® Investigators (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET® study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547–553Google Scholar
  73. 73.
    Malini PL, Strocchi E, Fiumi N, Ambrosioni E, Ciavarella A (1999) ACE inhibitor-induced cough in hypertensive type 2 diabetic patients. Diabetes Care 22:1586–1587PubMedCrossRefGoogle Scholar
  74. 74.
    Nicholls MG, Gilchrist NL (2005) Cough with ACE inhibitors: a bigger problem in some racial groups? Cardiovasc Drugs Ther 19:173–175PubMedCrossRefGoogle Scholar
  75. 75.
    Dullaart RP, Roelse H, Sluiter WJ, Doorenbos H (1989) Variability of albumin excretion in diabetes. Neth J Med 34:287–296PubMedGoogle Scholar
  76. 76.
    Bakris G, Burgess E, Weir M, Davidai G, Koval S, AMADEO Study Investigators (2008) Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 74:364–369Google Scholar
  77. 77.
    Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C, VIVALDI Investigators (2008) Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 23:3174–3183PubMedCrossRefGoogle Scholar
  78. 78.
    MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD (2006) Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 48:8–20PubMedCrossRefGoogle Scholar
  79. 79.
    Sengul AM, Altuntas Y, Kürklü A, Aydin L (2006) Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Res Clin Pract 71:210–219PubMedCrossRefGoogle Scholar
  80. 80.
    Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L, Parving HH (2005) Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 68:2829–2836PubMedCrossRefGoogle Scholar
  81. 81.
    Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, AVOID Study Investigators (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358:2433–2446PubMedCrossRefGoogle Scholar
  82. 82.
    Song JC, White CM (2001) Olmesartan medoxomil (CS-866). An angiotensin II receptor blocker for treatment of hypertension. Formulary 36:487–499Google Scholar
  83. 83.
    van Zwieten PA (2006) Angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans): similarities and differences. Neth Heart J 14:381–387Google Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Diabetes DivisionBaker IDI Heart and Diabetes InstituteMelbourneAustralia

Personalised recommendations